Here’s Why Johnson & Johnson (JNJ) Surged in Q3
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” third-quarter 2025 investor letter. A copy of…
5 Dividends That Beat Social Security’s Unpredictable COLA Adjustments
24/7/ Wall St. Social Security COLA dropped from 8.7% in 2023 to 2.5% in 2025. Realty Income pays…
Stock market today: Live updates
Traders work on the floor of the New York Stock Exchange (NYSE) at the opening bell in New…
5 Dividend Powerhouses That Belong in Every Retirement Portfolio Right Now
24/7 Wall St Verizon offers the highest yield at 6.59% with a 0.32 beta and 19 consecutive years…
Johnson & Johnson (JNJ) Announces Updated Results From the Phase 3 CARTITUDE-4 Study
Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in. Johnson & Johnson (NYSE:JNJ) announced…
1 Major Factor Behind the Healthcare Sector’s Recent Surge
Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other…
Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion
Johnson & Johnson has had the year 2025 circled, highlighted, bolded and underlined on its calendar for a…
Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers
AI chip maker Nvidia’s fresh partnerships with Eli Lilly and Johnson & Johnson point to a broader trend…
Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers
AI chip maker Nvidia’s fresh partnerships with Eli Lilly and Johnson & Johnson point to a broader trend…
Texas AG Ken Paxton moves to block Tylenol maker dividend amid lawsuit over marketing
Texas Attorney General Ken Paxton has filed a motion to block Kenvue, the maker of Tylenol, from issuing…
Trump, RFK Jr. and Texas lawsuits slam Kenvue
Kenvue, the company that makes Tylenol, is fighting on both the political and scientific fronts. The latest blow…
Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal
Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a…